Status:
UNKNOWN
Natriuretic Peptides as a Prognostic and Risk Stratification Tool in Assessment of Valvular Heart Disease
Lead Sponsor:
Assiut University
Conditions:
Valvular Heart Disease Stenosis and Regurgitation
Eligibility:
All Genders
18-80 years
Brief Summary
NPs can be used To detect subset of asymptomatic with subtle LV dysfunction for further evaluation and earlier referral for intervention and its correlation with echocardiographic finding.
Detailed Description
Each patient included in the study will undergo: 1. History taking: Analysis of patient symptoms and signs (dyspnea , orthopnea , Paroxysmal nocturnal dyspnea, lower limb edema , tachypalpitation...
Eligibility Criteria
Inclusion
- All patients echocardiographically diagnosed with significant valve lesions. Rheumatic Heart disease with significant but asymptomatic valvular Heart Disease especially (Mitral valve disease )(MS and MR) Gender: male \& female
Exclusion
- Cases with increased level of BNP as in :
- Renal impairment Advanced age and obesity Atrial fibrillation and acute coronary syndromes Prior lung diseases and acute illness
Key Trial Info
Start Date :
August 1 2022
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
January 1 2023
Estimated Enrollment :
40 Patients enrolled
Trial Details
Trial ID
NCT05439369
Start Date
August 1 2022
End Date
January 1 2023
Last Update
June 30 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Assiut University ,faculty of medicine
Asyut, Egypt